DR REDDYS LABORATORIES LTD (RDY)

Pharmaceutical Preparations · market cap $10.4B · as of 2026-07-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-23 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Dr. Reddy's Laboratories (RDY) is a large Indian multinational pharma company headquartered in Hyderabad with U.S. operations in New Jersey, producing over 190 medications, 60 APIs, and diagnostics across global markets. Its market cap stands at approximately $11.6B with 24,832 employees. The primary disclosed pipeline asset for CatalystAlert purposes is DFD05 Cream, currently in Phase 2 for common warts.

The catalyst path

2026-10-23 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
DFD05 Cream	Phase 2	Common Warts

Price & technical context

3-month

-9.8%

6-month

-8.9%

12-month

-9.7%

52-wk range

$11.38–$15.38

vs 50-day MA

+4.3%

vs 200-day MA

-5.2%

Realized vol

27.5%

Max drawdown

-30.4%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for RDY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.